Methods of treating blood disorders with vwf-targeted monospecific antibodies
AssigneeHemab ApS
InventorsHenrik Østergaard, Prafull S. Gandhi, Johan H. Faber, Catherine Rea, Benny Sørensen
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies that bind to von Willebrand factor to an epitope positioned at a cysteine knot (CK) domain. Such antibodies are useful for methods of treatment, such methods of treating one or more blood disorders characterized by excessive bleeding.
Claims534
A monospecific antibody comprising an antigen-binding site that specifically binds to an epitope of a von Willebrand Factor (VWF) protein positioned at a cysteine knot (CK) domain and a fragment crystallizable (Fc) region, wherein binding of the antibody to the VWF protein in blood plasma results in accumulation of the VWF protein in blood plasma as compared to a blood plasma level of the VWF protein in the absence of the antibody.
The monospecific antibody of any one of claims 1-11 and 371-378, wherein the antibody comprises:
- (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO:
- 355 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:
- 356, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:
- 357, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:
- 358;
- a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO:
- 359 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:
- 360, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:
- 361.
The monospecific antibody of any one of claims 1-598, wherein binding of the antibody to the VWF protein in blood plasma increases the blood plasma half-life of a FVIII protein as compared to the blood plasma half-life of the FVIII protein in the absence of the antibody.
Dependencies are inferred from the claim text.